'On consolidated basis

Quarter ended December 2024 compared with Quarter ended December 2023.

Net sales (including other operating income) of Gland Pharma has declined 10.43% to Rs 1384.05 crore.  Operating profit margin has jumped from 23.06% to 26.01%, leading to 1% rise in operating profit to Rs 359.96 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 32.76% to 32.14%.   Purchase of finished goods cost fell from 0.45% to 0.16%.   Employee cost increased from 24.38% to 25.19%.   Other expenses fell from 17.24% to 16.06%.   Power and Oil fuel cost fell from 4.52% to 4.02%.   

Other income rose 56.43% to Rs 58.49 crore.  PBIDT rose 6.26% to Rs 418.45 crore.  Provision for interest rose 332.20% to Rs 22.82 crore.  

PBDT rose 1.84% to Rs 395.63 crore.  Provision for depreciation fell 8.55% to Rs 96.33 ...

Pleaselogin & subscribe to view the full report.

More Reports

• 

  (01-Mar-2025)

  Foseco India

  OP up 17%
• 

  (28-Feb-2025)

  Schaeffler India

  Maintains double digit revenue growth and stable OPM
• 

  (28-Feb-2025)

  Sanofi India

  OP up 18.78%
• 

  (28-Feb-2025)

  KSB

  Net up 33% largely on higher sales, higher OI and lower taxation